The prognostic value of D-dimer levels in metastatic osteosarcoma patients treated with second-line chemotherapy

// Yujing Huang 1, * , Bangjian Liu 2, * , Yuanjue Sun 1 , Jianjun Zhang 1 , Yang Yao 1 , Aina He 1 1 Department of Oncology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, 200233 Shanghai, People’s Republic of China 2 Department of Neurology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, 200233 Shanghai, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Aina He, email: ai_na_he@yahoo.com Yang Yao, email: yangyao12@yahoo.com Keywords: D-dimer, osteosarcoma, chemotherapy response, prognosis, second-line chemotherapy Received: March 15, 2016 Accepted: August 09, 2016 Published: August 24, 2016 ABSTRACT We performed a retrospective analysis of 32 metastatic osteosarcoma cases to examine the prognostic value of the plasma D-dimer level. We assessed the D-dimer level before second-line chemotherapy (D1) and the D-dimer level after two cycles of second-line chemotherapy (D2). The change in D-dimer level (ΔD) was defined as D2 minus D1. The overall survival (OS) of patients with a high D1 was significantly shorter than those with a low D1 (median OS, 4.7 vs. 16.2 months, P=0.001). Similar results were observed for the D2 (median OS, 4.7 vs. 8.6 months, P=0.033). Multivariable analysis demonstrated that a high D1 (hazard ratio, 3.375; 95% confidence interval, 1.133–10.053; P=0.029) was an unfavorable independent prognostic factor. The mean D2 of 11 patients with stable disease decreased by 0.69 mg/mL compared to the D1 (P = 0.016). The mean D2 increased by 1.47 mg/mL compared to the D1 in 21 patients with progressive disease (P = 0.004). The data suggest that D-dimer may serve as a prognostic biomarker for metastatic osteosarcoma patients treated with second-line chemotherapy.